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ABSTRACT
Background    To ensure safe performance in robotic 
surgery, the Minimal Invasive Surgery Center (MISC) is 
composed of the anesthesiology department, five surgery 
departments and co-medical staff in our institution. The 
objective of this study was to evaluate the outcomes of 
different types of robotic surgeries for cancer treatment (n 
= 326) from different surgery departments in the MISC. 
Methods    The outcomes of robot-assisted radical 
prostatectomy (RARP), partial nephrectomy (RAPN), 
transoral robotic surgery (TORS) for pharyngeal cancer, 
and robotic surgery for lung, gastric and rectal cancer 
were evaluated using the similar concept of pentafecta 
in RARP. 
Results    The pentafecta rates of RARP and robotic 
surgery for rectal cancer were 33.3 and 56.5%, respec-
tively. The tetrafecta rates of RARP (excluding potency 
evaluation from pentafecta) and TORS were 48.4 and 
57.1%, respectively. The trifecta rates of RAPN, robotic 
surgeries for lung and gastric cancer were 75.9, 74.2 and 
84.2%, respectively. The failure of tetrafecta in RARP 
achievement was significantly associated with high risk 
than with low risk according to National Comprehensive 
Cancer Network classification.
Conclusion    This is the world’s first comprehensive 
evaluation of different types of robotic surgeries for 
cancer treatment in the constitutional framework of an 
academic institution. MISC, which provides the consti-
tutional framework of an academic institution, is provid-
ing immeasurable benefits in terms of robotic surgery 
quality, and it may ultimately lead to high penta-, tetra-, 
and trifecta rates for robotic surgeries for cancer treat-
ment in all surgical departments.
Key words  evaluation; outcome; robotic surgery
Robot-assisted radical prostatectomy (RARP) using 
the da Vinci surgical system started in 20001 and it has 
spread rapidly while retaining the concept of minimal 
invasive surgery. Although RARP was introduced in 
2006 in Japan, the spread of RARP has been very slow 
because of the off-label application of Japanese health 
insurance over this time. However, the Japanese Minis-
try of Health, Labor and Welfare allowed the application 
of health insurance for RARP on April 2012; therefore, 
the rapid spread of RARP is ongoing. A concern with 
regard to the rapid spread of new surgical innovation is 
the issue of patient safety. Reduced patient safety occurs 
due to insufficient preparation and inadequate surgical 
techniques during the introduction of a new technology. 
To eliminate such concerns, the introduction and im-
plementation of robotic surgeries in our institution were 
controlled by MISC, which performs robotic surgeries 
comprehensively not only in urology but also in other 
surgical departments. Recently, we reported our initial 
experience of 100 patients treated by RARP with a focus 
on constitutional introduction and implementation based 
on MISC.2 Since the initial experience of all robotic 
surgeries from different surgical departments, the case 
numbers of robotic surgeries have been continuously 
growing. The next aim of MISC after completion of the 
safe introduction of robotic surgery is the evaluation of 
robotic surgical outcomes. 
 Trifecta was introduced by Bianco et al. to evaluate 
the outcomes of RARP, aiming for the coexistence of 
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cancer control and functional preservation.3 Along with 
increased patient demands and greater expectations of 
surgical interventions, a new and more comprehensive 
method for reporting outcomes in RARP, i.e., the penta-
fecta, was proposed.4 Similarly, trifecta was advocated 
in robot-assisted partial nephrectomy (RAPN) for meet-
ing high quality surgical goals, including cancer control, 
functional preservation and absence of complications.5 
Despite the concrete surgical goals of robotic surgeries 
in the urological field, such goals seem to be obscure in 
robotic surgeries in other surgical departments. There is 
a concern with regard to the disappearance of sustained 
efforts by expert surgeons without concrete surgical 
goals. Therefore, we performed a comprehensive evalua-
tion of the different types of robotic surgeries for cancer 
treatment in MISC, which provides the constitutional 
framework of our academic institution.
MATERIALS AND METHODS
The role of MISC in robotic surgery; Constitutional 
framework of our institution
The urology staff started performing RARP in October 
2010 as the first robotic surgery in our institution. MISC 
was organized six months after the first RARP, and it 
consisted of all of the departments related to robotic 
surgery including anesthesiology, urology, gynecology, 
respiratory and digestive surgery, otorhinolaryngology, 
operation room nurses, medical engineers and medical 
clerks. From the viewpoint of safe implementation of ro-
botic surgery, each surgery was performed under the su-
pervision of MISC. For instance, certification for surgery 
type and the console surgeon were authorized by MISC. 
Specifically, MISC has “termination order” authority, 
which is exercised when there is excessive bleeding or 
an extended surgical time (Fig. 1). Robotic surgery must 
be converted into another type of surgery, such as open 
conversion, once the order is given. Each robotic surgery 
case in all surgery departments is checked and discussed 
pre- and postoperatively at the regular meetings held by 
MISC twice per month. 
Department:    Urology                      
Surgery type:    Robot-assisted radical prostatectomy    
     (Limited lymphadenectomy)   
 
1) Standard operation time:        5   hours       
 
2) Basal condition of termination order 
 a) Breakdown or malfunction of robotic surgical system 
 b) Malfunction of robotic surgical equipment 
 c) Excess bleeding:       more than    2000       mL         
 d) Excess operating time:       more than       8     hours        
 
3) Other conditions of the termination order 
 a) When operators recognize unexpected intra-operative 
  findings of advanced cancer 
 b) When it is obvious that other organ injuries occur 
 c) When anesthetists recognize critical problem in the 
  general care of the patient  
Department:      Digestive Surgery              
Surgery type:    Robot-assisted low anterior resection 
 
 
1) Standard operation time:          6    hours       
 
2) Basal condition of termination order 
 a) Breakdown or malfunction of robotic surgical system 
 b) Malfunction of robotic surgical equipment 
 c) Excess bleeding:         more than    500       mL         
 d) Excess operating time:         more than     10      hours        
 
3) Other conditions of the termination order 
 a) When operators recognize the difficulty of proceeding 
  with the operation based on an anatomical abnormality 
  or adhesion 
 b) When anesthetists recognize a critical problem in the 
  general care of the patient 
Fig. 1. The termination order (English version) for RARP and robotic surgery for rectal cancer is shown. The original docu-
ments are described in Japanese. RARP, robot-assisted radical prostatectomy. 
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Patients
A total of 500 cases were treated by robotic surgeries 
from October 2010 to September 2015 in MISC. Among 
these cases, 326 cases were treated by robotic surgery 
for cancer therapy and followed for more than 12 months 
(according to the criteria of patients in the evaluation of 
pentafecta4) and were enrolled in the study. The median 
follow-up duration was 24.2 months (range: 12.5–54.2). 
The details of the 326 cases were RARP (n = 217), 
RAPN (n = 29), robotic surgery for lung (n = 31), gastric 
(n = 19) and rectal (n = 23) cancers, and transoral robot-
ic surgery (TORS) for pharyngeal cancer (n = 7) (Table 
1). The study was approved by the Ethics Committee of 
Tottori University Faculty of Medicine (Approved No. 
1602A125).
Definition of penta and tetrafecta in RARP and tri-
fecta in RAPN
The definition of pentafecta in RARP complied with 
the robust previous literature,4 with some modifications 
only in the definition of potency. Because of the lower 
incidence of preoperatively potent patients, compared 
with the incidence of patients in Western countries, and 
the small number of patients who underwent bilateral 
nerve sparing procedures, the definition of potency 
was modified as follows. The recovery of potency was 
defined in cases in which a preoperatively potent pa-
tient (International Index of Erectile Function erectile 
function domain > 21) underwent bi- or unilateral nerve 
sparing procedures and recovered to International Index 
of Erectile Function erectile function domain > 17, with 
and without the use of PDE5 inhibitors postoperatively. 
Because the patient cohort that the pentafecta rate was 
able to evaluate consisted of a small number of patients, 
tetrafecta rate (excluding potency evaluation) was also 
evaluated in RARP. The most current use of the defi-
nition of trifecta in RAPN5 was employed in the study, 
i.e., warm ischemia time (WIT) less than 25 minutes, 
negative surgical margins and no perioperative compli-
cations.  
Table 1. Robotic surgery types for cancer treatment and their number of cases
Department Surgery type No. of cases
Urology Robot-assisted radical prostatectomy (RARP) 217
Robot-assisted partial nephrectomy (RAPN) 29
Respiratory surgery Robotic surgery for lung cancer 31
Digestive surgery Robotic surgery for gastric cancer 19
Robotic surgery for rectal cancer 23
Otorhinolaryngology Transoral robotic surgery (TORS) for pharyngeal cancer 7
Total 326
Table 2. Definition of penta, tetra and trifecta in each type of robotic surgery
Surgery type Definition of penta, tetra or trifecta achievement
RARP (Pentafecta) 1) No biochemical recurrence, 2) Negative surgical margin, 3) Continence recovery (no pad), 
4) Potency recovery, 5) No complication
RARP (Tetrafecta) 1) No biochemical recurrence, 2) Negative surgical margin, 3) Continence recovery (no pad), 
4) No complication
RAPN (Trifecta) 1) Negative surgical margin, 2) Warm ischemia time (WIT) ≤ 25 min., 3) No complication
Robotic surgery for rectal 
cancer (Pentafecta)
1) No recurrence, 2) Negative surgical margin, 3) Normal voiding, 4) Normal defecation, 
5) No complication
TORS (Tetrafecta) 1) No recurrence, 2) Negative surgical margin, 3) Normal swallowing, 4) No complication
Robotic surgery for lung and 
gastric cancer (Trifecta) 1) No recurrence, 2) Negative surgical margin, 3) No complication
RAPN, robot-assisted partial nephrectomy; RARP, robot-assisted radical prostatectomy; TORS, transoral robotic surgery; WIT, warm 
ischemia time.
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Definition of pentafecta in robotic surgery for rectal 
cancer, tetrafecta in TORS, and trifecta in robotic 
surgeries for lung and gastric cancer
Because of the lack of evaluative measures for robotic 
surgical outcomes in the surgical departments other than 
urology, we originally defined penta, tetra and trifecta. 
Considering the transition from trifecta to pentafecta 
in RARP and the advocacy of trifecta in RAPN, three 
issues were included, if possible, in the study, i.e., “com-
plete cancer control,” “functional preservation” and “no 
perioperative complications.” The issue of “complete 
cancer control” included both negative surgical margins 
and no postoperative relapse except for RAPN. Because 
the issue of “functional preservation” has not been es-
tablished in robotic surgeries for lung and gastric cancer, 
it was excluded from these two types of surgery. With 
regard to the issue of “no perioperative complications,” 
complications occurring during the surgical procedure 
or within 90 d after surgery were documented and clas-
sified according to the Clavien-Dindo (CD) classifica-
tion.6 The definitions of penta, tetra or trifecta in each 
type of robotic surgery in the MISC are summarized in 
Table 2. 
Statistical analysis
Univariate and multivariate logistic regression analyses 
were used to analyze the factors predictive of achieving 
tri, tetra and pentafecta in each type of robotic surgery, 
with P < 0.05 considered statistically significant.
RESULTS
The types, case numbers, complications and open 
conversion rates of all robotic surgeries in the 
MISC
A total of 500 cases undergoing 14 types of robotic sur-
gery were treated from the first case of robotic surgery 
until September 2015 in the MISC. Serious complica-
tions (CD grade ≥ Ⅲ) were recognized in 6 cases (1.2%). 
Open conversion was performed in only one case (0.2%), 
which was treated by robotic surgery for gastric cancer 
not because of an emergency reason but because of diffi-
culty in the robotic procedure due to unexpected cancer 
progression. 
The evaluation of robotic surgical outcomes for 
cancer treatment according to penta, tetra and tri-
fecta in the MISC
Only patients who successfully met all of the afore-
mentioned criteria in each type of robotic surgery were 
considered to achieve penta, tetra or trifecta. The penta, 
tetra and trifecta rate (percentage) are the rates of cas-
es in which surgical outcome has met successfully all 
of the criteria. For instance, the trifecta rate in robotic 
surgery for gastric cancer is the rate of cases against 
total cases in which surgical outcome has met success-
fully “no recurrence,” “negative surgical margin” and 
“no complication.” The pentafecta rates of RARP (n = 
24) and robotic surgery for rectal cancer were 33.3 and 
56.5%, respectively. The tetrafecta rates of RARP (n = 
217) and TORS were 48.4 and 57.1%, respectively. The 
trifecta rates of RAPN, robotic surgeries for lung and 
gastric cancer were 75.9, 74.2 and 84.2%, respectively. 
The penta and tetrafecta rates of RARP, robotic surgery 
for rectal cancer and TORS are shown with their radar 
graphs (Fig. 2). Similarly, the trifecta rates of RAPN and 
robotic surgery for lung and gastric cancer are shown 
with their radar graphs (Fig. 3).
The predictive factors for achieving tri, tetra and 
pentafecta in each type of robotic surgery for 
cancer treatment 
TORS was excluded from the analyses because of the 
small number of cases. The factors analyzed were pa-
tient and tumor backgrounds, which reflected patients 
generally and tumors specifically. Moreover, the ana-
lyzed factors were chosen based on the concept of easy 
use for clinical practice. Age, body mass index (BMI), 
and the American Society of Anesthesiologists (ASA) 
risk classification system score were analyzed in each 
type of robotic surgery. Other than these data, the fol-
lowing factors were analyzed. For RARP (penta and 
tetrafecta achievement), preoperative prostate specific 
antigen (PSA), risk stratification in the National Com-
prehensive Cancer Network (NCCN), T stage, Gleason 
score and existence of lymph node metastasis in final 
pathology were considered; for robotic surgery for rectal 
(pentafecta achievement), gastric (trifecta achievement) 
and lung cancers (trifecta achievement), sex, preoper-
ative carcinoembryonic antigen (CEA) and T stage in 
final pathology were considered; and for RAPN (trifecta 
achievement), sex, renal nephrometry score and whether 
malignant or benign in final pathology were considered. 
From all of the analyses, only one independent factor 
was revealed that was predictive of tetrafecta achieve-
ment in RARP (Table 3), which indicated that the failure 
of tetrafecta achievement was significantly associated 
with high risk than with low risk according to NCCN 
classification. 
DISCUSSION
Almost 10 years have passed since the introduction of 
trifecta in RARP, but only 11 original articles have re-
ported trifecta rates, with a mean value of 58% (range 
20–83%).7 Although the surgical goal in RARP has been 
139
Evaluation of robotic surgical outcome
0
20
40
60
80
100
No biochemical
recurrence
Negative
surgical margin
No
complication
Continence
Potency
RARP (pentafecta)
Pentafecta
rate = 33.3%
0
20
40
60
80
100
No biochemical
recurrence
Negative
surgical margin
No
complication
Continence
RARP (tetrafecta)
Tetrafecta
rate = 48.4%
Robotic surgery for rectal cancer (pentafecta)
0
20
40
60
80
100
No recurrence
Negative surgical
margin
No complicationNormal voiding
Normal
defecation
0
20
40
60
80
100
No
recurrence
Negative
surgical
margin
No
complication
Normal
swallowing
TORS (tetrafecta)
n = 7
Tetrafecta
rate = 57.1%
n = 217
n = 24 n = 23
Pentafecta rate = 56.5%
0
20
40
60
80
100
Negative surgical
margin
No complicationWIT ≤ 25 min
RAPN (trifecta)
n = 29
Trifecta rate 
= 75.9%
0
20
40
60
80
100
No recurrence
Negative
surgical
margin
No
complication
Robotic surgery for lung cancer (trifecta)
n = 31
Trifecta rate 
= 74.2% 0
20
40
60
80
100
No recurrence
Negative
surgical
margin
No
complication
Robotic surgery for gastric cancer (trifecta)
n = 19
Trifecta rate 
= 84.2%
Fig. 2. The radar graphs of penta and tetrafecta achievements in RARP and of robotic surgery for rectal cancer 
and TORS are shown. In each radar graph, single components and their successful rates are also shown. RARP, 
robot-assisted radical prostatectomy; TORS, transoral robotic surgery. 
Fig. 3. The radar graphs of trifecta achievements in RAPN and robotic surgeries for lung and gastric cancer are 
shown. In each radar graph, single components and their successful rates are also shown. RAPN, robot-assisted 
partial nephrectomy, WIT, warm ischemia time.
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changed from trifecta to pentafecta, the number of stud-
ies indicating pentafecta rates has been limited. Three 
major studies, in which more than one hundred patients 
were treated by RARP, demonstrated pentafecta rates of 
70.8, 60.4 and 45.6%, respectively. 4, 8, 9 There have been 
criticisms that trifecta and pentafecta systems are not 
appropriate reporting tools for the majority of patients 
undergoing radical prostatectomy (RP) because they are 
only applicable in preoperatively continent and potent 
patients who receive bilateral nerve-sparing procedures. 
Recently, the survival, continence, and potency, so 
called SCP classification, has been advocated to classify 
appropriately all patients who undergo RP according to 
the oncologic and functional outcomes of relevance to 
them on an individual basis.7 The diverse sexual activity 
and desire of patients treated by RP worldwide defi-
nitely affects the usefulness of the pentafecta system. 
In Asian patient cohorts, only one study demonstrated 
a pentafecta rate of 72.9% in 170 patients treated by 
laparoscopic RP.10 It is presumed that patients’ sexual 
activity and desire in Japan are lower than those of pa-
tients from Western countries. Moreover, the relatively 
high incidence of patients in Japan who underwent plain 
localization of cancer foci in the prostate by frequent 
use of magnetic resonance imaging (MRI) indicated 
Table 3. Multivariate analysis for predictive factors of achieving tetrafecta in RARP
Factor OR (95% CI) P value
Age at surgery (ys) 1.040 (0.993–1.090) 0.0949
BMI (kg/m2) 1.000 (0.899–1.111) 0.9933
ASA score Class Ⅰ 1.000 (referent)
Class Ⅱ 0.865 (0.483–1.549) 0.6246
Initial PSA (ng/mL) 1.009 (0.957–1.065) 0.7272
NCCN risk Low 1.000 (referent)
Intermediate 0.627 (0.239–1.641) 0.3411
High 0.346 (0.125–0.955) 0.0405 
T stage (final pathology) 0, 2a 1.000 (referent)
2b 1.377 (0.345–5.505) 0.6506
2c 0.824 (0.396–1.713) 0.6032
≥ 3a 1.186 (0.432–3.257) 0.7403
Gleason score (final pathology) 6 1.000 (referent)
7 1.675 (0.643–4.364) 0.2913
≥ 8 1.332 (0.425–4.171) 0.6227
Lymph node metastasis 
(final pathology)
Absent 1.000 (referent)
Present 0.188 (0.020–1.797) 0.1466
ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; NCCN, National Comprehensive Cancer 
Network; OR, odds ratio; PSA, prostate specific antigen; RARP, robot-assisted radical prostatectomy; ys, years.
unilateral rather than bilateral nerve-sparing procedures. 
Therefore, we investigated for the first time worldwide 
the tetrafecta rate, excluding the potency term from pen-
tafecta, in patients treated by RARP. Because there have 
been no studies indicating tetrafecta rates, our result 
of 48.4% should be considered a pilot value. Our study 
demonstrated that the failure of tetrafecta achievement 
was significantly associated with high risk than with 
low risk according to NCCN classification. Because we 
performed extended lymphadenectomy and wide dissec-
tion of the prostate in high risk patients, it seemed to be 
the necessary consequence that high risk according to 
NCCN classification was revealed as factor predictive of 
the failure of tetrafecta.
 There has been a debate over the definition of 
functional preservation in trifecta for RAPN. Hung et 
al. demonstrated the outcomes of 534 patients treat-
ed by laparoscopic partial nephrectomy (LPN) and 
RAPN based on the trifecta concept, with failure of 
renal functional preservation defined as a greater than 
10% reduction in the actual estimated glomerular fil-
tration rate (eGFR), compared with that of the volume 
predicted postoperative eGFR rate.11 In contrast, Buffi 
et al. proposed an evaluation measure called “MIC” 
(margin, ischemia and complications) in nephron spar-
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ing surgery.12 Hung et al. argued that ischemia was not 
necessarily the most important surgical factor affecting 
postoperative renal function. However, the majority of 
studies have defined WIT < 25 min. as an indicator of 
functional preservation, based on a study indicating a 
cut-off time for warm ischemia in solitary kidney cases 
treated by partial nephrectomy.13 Trifecta rates of RAPN 
have been demonstrated, in the setting of retrospective 
comparison between LPN and RAPN, as 58.7 and 70% 
derived from 251 and 1185 cases treated by RAPN, re-
spectively.5, 14 If having complications with ≤ CD grade 
Ⅱ was defined as a successful criterion, the trifecta rate 
increased to 81.8 % in 44 cases treated by RAPN.15 Al-
though the number of cases in our cohort was lower than 
those in the aforementioned studies, our trifecta rate 
of 75.9% in RAPN seemed to be excellent. This result 
might have three causes. The first is the expert skill of 
the surgeon (Co-author; A.T.), who had sufficient expe-
rience in LRP and RARP. Unlike RARP, all cases of 
RAPN were performed by him. The second cause was 
the MISC management, especially the regular confer-
ences at which all robotic cases were assessed pre- and 
postoperatively. The third was the intraoperative naviga-
tion system used, with SYNAPSE VINCENT (Fujifilm, 
Tokyo, Japan) film technology, which could draw renal 
vascular images precisely.
 First, there was no other way to recognize our re-
sults of penta, tetra and trifecta in robotic surgeries other 
than using the urological field for pilot values because 
no studies have been conducted previously. However, it 
is universal to use the items of “complete cancer control” 
and “no perioperative complication” in the evaluation of 
the surgical outcome for various kinds of cancer treat-
ment. To unify the matter of complete cancer control in 
the study, negative surgical margins and no postopera-
tive relapse were employed in all of the robotic surgery 
types except for RAPN. However, there were no studies 
investigating surgical margin status in robotic surger-
ies for lung or gastric cancer. Complete cancer control 
should be evaluated in the future employing other factors 
in these two types of robotic surgery because there are 
some potent prognostic indicators, such as lymph node 
pathology, especially in gastric cancer. In the compari-
son of cancer control between robotic and laparoscopic 
surgeries for rectal cancer, circumferential and distal 
resected margin positive rates were demonstrated as be-
ing equivalent between the two approaches.16–19 In con-
trast, the positive surgical margin rate of 4.3% in TORS, 
which was indicated from a prospective, multicenter 
study, was suggested not to be inferior to other types of 
transoral minimally invasive surgeries.20 In our study, 
the positive surgical margin rates with robotic surgery 
for rectal cancer and TORS were 0% and 28.6%, respec-
tively. However, the evaluation of TORS was difficult 
because of the small number of cases in our study (n = 7). 
 With regard to evaluation of visceral functional 
preservation in robotic surgeries with penta, tetra and 
trifecta other than in urological field, we chose some 
appropriate and established items. “Normal defecation” 
and “normal voiding” have been established in the eval-
uation of robotic surgery for rectal cancer as well as 
“normal swallowing” in the evaluation of TORS. Void-
ing and sexual function were demonstrated to be better 
after robotic surgery than after laparoscopic surgery for 
rectal cancer using uroflowmetry and questionnaires.21, 22 
The functional preservation of voiding and defecation, 
rather than sexual function, based on the collectable data 
in our study, was generally satisfactory (18 of 23 cases; 
78.3%). Percutaneous endoscopic gastrostomy depen-
dency after TORS which was defined as the surrogate 
factor for swallowing evaluation reported in 5% of cases, 
and the rate was equivalent to those in other treatment 
modalities for oropharyngeal malignancy.20 Finally, the 
complication rates in all types of robotic surgery, except 
RARP and RAPN, were demonstrated to be better than 
or equivalent to those in open or other minimally inva-
sive surgeries.23–26 Although complications occurred in 
12 of 23 cases (52.2%) in robotic surgery for rectal can-
cer, most of them (11 of 12 cases) were minor (CD grade 
≤ Ⅱ). In other types of robotic surgery, the complication 
rates were generally low in our study.
 Our study has certain limitations. The first is that 
there were no data with regard to penta, tetra or trifecta 
rates in robotic surgeries other than from the urologi-
cal field. Even the concept of these surgical goals was 
not present. Therefore, our data were only pilot values. 
However, the first trial of the evaluation of robotic sur-
gical outcomes, based on the concept of penta, tetra 
and trifecta, in surgical departments other than urology 
should be initiated in urology because urologists are the 
pioneers of robotic surgery. Other limitations include 
the retrospective nature of the study, as well as its sin-
gle-center trial design and the small sample size. Exter-
nal validation of the penta, tetra and trifecta rates in all 
types of robotic surgery for cancer treatment will facil-
itate the comprehensive evaluation of robotic surgical 
outcomes not only in urology but also in other surgical 
fields. 
 In conclusion, the world’s first comprehensive eval-
uation of different types of robotic surgeries for cancer 
treatment in the constitutional framework of an academ-
ic institution could result in the safer implementation of 
robotic surgeries with higher quality. MISC is a useful 
construction that can evaluate robotic surgical outcomes 
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based on the same measures that extend across the 
boundaries among different surgical departments. Al-
though penta, tetra and trifecta rates in surgical depart-
ments other than urology are only pilot values, it is valid 
to initiate a comprehensive evaluation of robotic surgical 
outcomes using data from urologists, who are the pio-
neers of robotic surgery. 
The authors declare no conflict of interest. 
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